| Co-Investigator(Kenkyū-buntansha) |
三井 薫 鹿児島大学, 医歯学域医学系, 講師 (40324975)
伊地知 暢広 鹿児島大学, 医歯学域医学系, 助教 (80380624)
入江 理恵 鹿児島大学, 医歯学域医学系, 助教 (90381178)
王 宇清 鹿児島大学, 医歯(薬)学総合研究科, 特任研究員 (20505143)
|
|---|
| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2015: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2014: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2013: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Outline of Final Research Achievements |
We have developed m-CRA-based technology and medicine that is superior to current oncolytic viruses. This study using stem cells produced the meaningful results, leading to clinical application of m-CRA for pediatric cancer. Survivin promoter was strongly activated in the undifferentiated pluripotent stem cells (PSCs) as well as cancer cells, but its activity was decreased in the differentiated PSCs, to which survivin-responsive m-CRA (Surv.m-CRA) exerted less cytotoxicity. A local injection of Surv.m-CRA may not damage normal stem cells, and Sur.m-CRA therapy should be safe for pediatric patients with cancer. These results contributed to the expansion of clinical application of Surv.m-CRA therapy to pediatric patients.
|
